Pyxis Oncology, Inc. Increase (Decrease) in Other Operating Assets and Liabilities, Net
Pyxis Oncology, Inc. (PYXS) reported Increase (Decrease) in Other Operating Assets and Liabilities, Net of $23.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet · last filed 2026-08-13
- Pyxis Oncology, Inc. increase (decrease) in other operating assets and liabilities, net for the quarter ending 2026-06-30 was $3.00K, a 83.33% decline year-over-year.
- Pyxis Oncology, Inc. increase (decrease) in other operating assets and liabilities, net for the quarter ending 2026-03-31 was $20.00K, a 0.00% change year-over-year.
- Pyxis Oncology, Inc. increase (decrease) in other operating assets and liabilities, net for the quarter ending 2025-12-31 was $14.00K, a 12.50% decline year-over-year.
- Pyxis Oncology, Inc. increase (decrease) in other operating assets and liabilities, net for the quarter ending 2025-09-30 was $19.00K, a 11.76% increase year-over-year.
- Pyxis Oncology, Inc. increase (decrease) in other operating assets and liabilities, net for fiscal 2025 was $71.00K, a 25.26% decline from fiscal 2024.
- Pyxis Oncology, Inc. increase (decrease) in other operating assets and liabilities, net for fiscal 2024 was $95.00K.
| Period end | Increase (Decrease) in Other Operating Assets and Liabilities, Net 3 month | Increase (Decrease) in Other Operating Assets and Liabilities, Net 6 month | Increase (Decrease) in Other Operating Assets and Liabilities, Net 9 month | Increase (Decrease) in Other Operating Assets and Liabilities, Net 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $23.00K 10-Q · filed 2026-08-13 | $37.00K derived: sum of 3 quarters · filed 2026-08-13 | $56.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $20.00K 10-Q · filed 2026-05-14 | $34.00K derived: sum of 2 quarters · filed 2026-05-14 | $53.00K derived: sum of 3 quarters · filed 2026-05-14 | $71.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $14.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $33.00K derived: sum of 2 quarters · filed 2026-03-23 | $51.00K derived: sum of 3 quarters · filed 2026-08-13 | $71.00K 10-K · filed 2026-03-23 |
| 2025-09-30 | $19.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $37.00K derived: sum of 2 quarters · filed 2026-08-13 | $57.00K 10-Q · filed 2025-11-03 | $73.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $18.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $38.00K 10-Q · filed 2026-08-13 | $54.00K derived: sum of 3 quarters · filed 2026-08-13 | $71.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $20.00K 10-Q · filed 2026-05-14 | $36.00K derived: sum of 2 quarters · filed 2026-05-14 | $53.00K derived: sum of 3 quarters · filed 2026-05-14 | |
| 2024-12-31 | $16.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $33.00K derived: sum of 2 quarters · filed 2026-03-23 | $95.00K 10-K · filed 2026-03-23 | |
| 2024-09-30 | $17.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $79.00K 10-Q · filed 2025-11-03 | ||
| 2024-06-30 | $62.00K 10-Q · filed 2025-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |